Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/02/24
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/25/24
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024GlobeNewsWire • 04/18/24
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024GlobeNewsWire • 03/05/24
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024GlobeNewsWire • 02/22/24
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/15/24
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/15/24
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to DeclineZacks Investment Research • 02/08/24
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024GlobeNewsWire • 02/02/24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease PortfolioGlobeNewsWire • 01/08/24
Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/04/24
Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia DrugInvestors Business Daily • 01/03/24
Agios Pharma's stock soars 19.6% on news of positive results in trial of treatment for rare blood disorderMarket Watch • 01/03/24
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-ThalassemiaGlobeNewsWire • 01/03/24
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024GlobeNewsWire • 01/02/24
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and ExpositionGlobeNewsWire • 12/10/23